Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries.

Smith, Dallas J; Bi, Huichang; Hamman, Josias; Ma, Xiaochao; Mitchell, Constance; Nyirenda, Kumbukani; Monera-Penduka, Tsitsi; Oketch-Rabah, Hellen; Paine, Mary F; Pettit, Syril; Pheiffer, Wihan; Van Breemen, Richard B; Embry, Michelle

Smith, Dallas J; Bi, Huichang; Hamman, Josias; Ma, Xiaochao; Mitchell, Constance; Nyirenda, Kumbukani; Monera-Penduka, Tsitsi; Oketch-Rabah, Hellen; Paine, Mary F; Pettit, Syril; Pheiffer, Wihan; Van Breemen, Richard B; Embry, Michelle.

Afiliación

Smith DJ; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Bi H; COVID-19 Response International Task Force, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Hamman J; School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Ma X; Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.
Mitchell C; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Nyirenda K; Health and Environmental Sciences Institute, Washington, DC, United States.
Monera-Penduka T; Department of Pharmacy, Kamuzu University of Health Sciences, Blantyre, Malawi.
Oketch-Rabah H; Research Unit for Safety of Herbs and Drugs, University of Zimbabwe, Harare, Zimbabwe.
Paine MF; United States Pharmacopeia, Rockville, MD, United States.
Pettit S; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.
Pheiffer W; Health and Environmental Sciences Institute, Washington, DC, United States.
Van Breemen RB; DSI/NWU Preclinical Drug Development Platform, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.
Embry M; Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, United States.

Front Pharmacol ; 14: 1210579, 2023.

Article en En | MEDLINE | ID: mdl-37502215

Palabras clave

COVID-19; PAXLOVID; drug-drug interaction (DDI); herb-drug interaction (HDI); herbal medicine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos